Eupraxia’s Billion-Dollar EoE Opportunity: Cantor Sees a Valuation Gap Ahead of December Data -( $AMGN $AZN $EPRX $REGN $SNY $TAK )

A $19 price target, a potential once-yearly treatment and a modest-market-share thesis put EPRX in focus

For biotechnology investors, the most compelling opportunities sometimes involve a familiar medicine delivered in an unfamiliar, and potentially more valuable, way. That is the investment case that is believed to be taking shape around Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX). In an October 7 research report titled, “Eupraxia EP-104GI (U.S. Only) EoE Valuation Simulations”, Cantor Fitzgerald maintained an Overweight rating and a $19 price target while outlining how the company’s experimental treatment for eosinophilic esophagitis, or EoE, could support substantial value in the United States alone. Against the report’s reference share price of $7.74, that target implies approximately 145% upside. The reference price is the figure published in Cantor’s report, not a live quote. The immediate catalyst is believed to be a Phase 2b interim readout for EP-104GI expected in December 2026. Cantor’s analysts believe positive results could send shares more than 100% higher as investors reassess the program’s clinical risk. That is an analyst expectation, not a forecast investors should mistake for a scheduled delivery. In biotechnology, December can bring presents, or additional questions. What makes the report notable is not simply its bullish conclusion. It is the argument underneath: Eupraxia may not need to dominate the EoE market to build a commercially meaningful business.

Cantor’s Core Thesis: A Small Share of a Large Market Can Matter

Cantor analysts Kristen Kluska, Ayan Hussein and Ross Fladeland describe Eupraxia as a top pick and report that investor inquiries about the company have increased ahead of the upcoming data. Their analysis concentrates on EP-104GI’s U.S. EoE opportunity, leaving international markets and additional potential indications outside the valuation simulations. The team constructs two patient-population frameworks:

• A base case starts with approximately 500,000 U.S. EoE patients and narrows that population to 200,000 potentially eligible adults after adjustments for age and patients adequately managed with existing approaches.
• A growth case assumes approximately 1 million U.S. patients later this decade, producing an eligible treatment population of 400,000 after the same adjustments.

Those figures are modeling assumptions, not confirmed counts of patients who would receive EP-104GI. Nevertheless, they illustrate why relatively modest adoption could generate considerable revenue. At an assumed annual gross price of $50,000, treating 20,000 patients would produce $1 billion in annual gross sales. That represents 10% penetration of Cantor’s base-case eligible population, or just 5% of its growth-case population. The bullish proposition is therefore less “win the entire market” than “earn a meaningful place in it.” For a clinical-stage company with a market capitalization of approximately $503 million in the report, that distinction carries weight.

EP-104GI: The Drug-Delivery Approach Behind the Investment Case

EP-104GI is an investigational extended-release formulation of fluticasone propionate, a corticosteroid, delivered through injections into the esophageal wall. Eupraxia’s proprietary Diffusphere technology is designed to release medicine locally over an extended period. EoE is an inflammatory disease that can make swallowing difficult and painful. Eupraxia’s approach targets the affected tissue directly, aiming to combine durable symptom control with localized drug delivery. Cantor sees the potential for a treatment administered approximately once a year, a possible differentiator from more frequently administered therapies. That interval remains a development objective supported by early observations, not an approved dosing schedule or an established outcome for the broader patient population. The commercial appeal is easy to understand: sustained control could reduce the burden of repeated treatment. But the procedural trade-off matters. EP-104GI is not a simple annual injection under the skin; the higher-dose regimens under study involve 20 esophageal-wall injections during a treatment procedure. Investors should weigh potential durability against that administration requirement. The attraction is not that Eupraxia has made treatment disappear. It is that the company is trying to concentrate it into a much less frequent intervention.

Early Clinical Results Give the Durability Thesis Substance

The report arrives against a backdrop of encouraging, but still preliminary, clinical observations. In an August 13 company update, Eupraxia reported that the proportion of patients with moderate or severe difficulty swallowing in RESOLVE cohorts 7-9 fell from 77% at baseline to 25% at both 24 and 52 weeks after treatment. Moderate or severe painful swallowing declined from 62% at baseline to 25% at those same time points. Those results require context. The baseline analysis included 13 patients, compared with eight assessed at week 52. The Phase 1b/2a portion of RESOLVE was open-label and dose-escalating, without a placebo comparison, and the percentages described symptom-category distributions at each visit rather than paired changes for every individual. They are encouraging signals, not definitive evidence of efficacy. A September 30 update, added that 64% of patients across cohorts 5–9 met the study’s definition of clinical remission at 52 weeks after a single administration. That definition was a reduction of at least three points in the Straumann Dysphagia Index relative to baseline. Taken together, these observations help explain Cantor’s conviction: symptom improvement appears capable of persisting well beyond the immediate treatment period. The forthcoming randomized, placebo-controlled Phase 2b analysis must now test whether that promise holds under more rigorous conditions.

December’s Readout Is About Tissue Health and Everyday Function

Cantor identifies two measures as particularly important to investors:

• EoEHSS, the Eosinophilic Esophagitis Histology Scoring System, which assesses disease features in esophageal tissue.
• DSQ, the Dysphagia Symptom Questionnaire, which measures patients’ difficulty swallowing.

The distinction matters. A treatment’s effect on tissue and its effect on daily symptoms are related, but they are not interchangeable. Cantor’s investment case looks for a persuasive result on both fronts. The analysts believe the relevant benchmark is performance at least broadly comparable with established treatments such as Sanofi’s (SNY) & Regeneron’s (REGN) Dupixent or Eohilia, accompanied by a differentiated treatment interval. They also caution that investors need to understand different ways of calculating EoEHSS when interpreting results.Cross-trial comparisons deserve restraint. Different populations, study designs, follow-up periods and endpoint definitions mean that separate studies cannot establish head-to-head superiority. Eupraxia’s December data can strengthen its own case without settling every competitive question.

Competition Validates the Market and Raises the Bar

Eupraxia is pursuing an opportunity that already attracts major pharmaceutical companies. Dupixent, jointly developed by Sanofi (NASDAQ: SNY; Euronext Paris: SAN) and Regeneron Pharmaceuticals (NASDAQ: REGN), received its initial U.S. EoE approval in May 2022. The FDA expanded the indication in January 2024 to include patients aged one year and older weighing at least 15 kilograms. Takeda Pharmaceutical (NYSE: TAK; Tokyo: 4502) also markets Eohilia, an oral budesonide treatment approved for EoE. Cantor includes it among the existing therapies against which investors will assess EP-104GI. Meanwhile, Amgen (NASDAQ: AMGN) and AstraZeneca (NASDAQ: AZN; LSE: AZN) announced positive Phase 3 results for Tezspire in EoE on August 27, 2026. The companies reported statistically significant and clinically meaningful improvements in histologic remission and swallowing symptoms at week 24, sustained through week 52. The trial evaluated administration every four weeks. For Eupraxia, this competitive activity has two implications. It confirms that EoE is a serious drug-development market, but it also means any newcomer must demonstrate a compelling reason for physicians and patients to choose it. Cantor believes a potentially once-yearly, locally delivered therapy could occupy a distinct position alongside other treatments rather than needing to displace them all. That is a more measured thesis than declaring every competitor obsolete, a phrase that tends to age poorly in pharmaceutical research.

Reading the Valuation Correctly: $19 Is the Target, Not $116

Cantor’s report contains striking scenario values, but they should not be confused with its formal recommendation. The firm’s published 12-month price target remains $19. It is based on a probability-adjusted discounted cash-flow analysis extending through 2035, using a 12% discount rate and a 0% terminal-growth assumption. The broader simulations explore how market penetration and probability of success change estimated value:

• In the base case, 10% peak penetration produces estimated peak net sales of $800 million in 2035 and an implied value of $23 per share at a 100% probability of success.
• At 30% base-case penetration, estimated peak net sales reach $2.4 billion, with an implied value of $72 per share at 100% probability of success.
• In the growth case, 5% penetration produces $800 million in estimated peak net sales and a $27 implied share value at 100% probability of success.
• At 20% growth-case penetration, estimated peak net sales reach $3.2 billion, supporting a $116 implied share value at 100% probability of success.

These are conditional outputs, not additional price targets. A 100% probability-of-success assumption effectively removes development failure from that part of the valuation exercise, an especially important distinction for a drug still in clinical testing. The less optimistic cases reveal the sensitivity. At 10% penetration in the base model, implied value falls to $14 per share at a 70% probability of success and $6 at 40%. Some low-penetration scenarios generate zero or negative modeled equity values. Cantor’s work therefore supports a substantial upside argument while also showing exactly why clinical execution matters.

The Billion-Dollar Sales Headline Needs a Net-Revenue Footnote

One detail separates useful analysis from exuberant arithmetic: gross pricing is not the same as realized revenue. Cantor’s initial sales illustrations use an assumed $50,000 annual gross price. Its valuation simulations then apply a 20% gross-to-net discount, reducing modeled revenue per patient to $40,000. That is why 20,000 treated patients generate $1 billion in the gross-sales illustration but $800 million in the valuation model. The numbers are consistent; they answer different questions. The simulations also assume a late-2029 launch and peak sales in 2035. Neither the commercial launch date nor the pricing assumption is an established outcome. The opportunity may be large, but the revenue is not around the next quarterly corner.

International Markets and Additional Indications Remain Outside the Model

One appealing feature of Cantor’s analysis is its limited geographic scope. The scenarios focus on U.S. EoE rather than adding international revenue or assigning value to every possible future application. The report identifies other regions and potential indications, including gastrointestinal strictures and fibrostenosing Crohn’s disease, as possible sources of upside beyond the simulations. Those opportunities would require their own development, regulatory and commercial work; they should not be treated as banked value. For many, the distinction is useful. The core thesis can be evaluated on the lead program, while broader platform opportunities remain contingent additions rather than necessary ingredients.

The Bullish Case Comes With Real Risks

Eupraxia remains a clinical-stage biotechnology company. EP-104GI must demonstrate convincing efficacy and safety, advance through further development and obtain regulatory approval before commercial sales can become reality. Also note, that the assumed treatment price and market share depend on payer coverage and physician adoption, not simply on a successful trial. Cantor also identifies financing, competition, reimbursement and commercial execution as material risks. Funding is particularly relevant because additional financing could dilute existing shareholders. Note that on August, 11, 2026, Eupraxia announced its financial results for the second quarter of 2026, which stated that the Company had cash and cash equivalents of $52.4 million and short-term investments of $81.2 million as of June 30, 2026, up from an aggregate cash balance of $80.6 million at the end of the fourth quarter of 2025. They also confirmed that these funds are being used to fund clinical trials in EP-104GI and for general and administrative expenses, working capital needs and other general corporate purposes. The Company also anticipates that existing cash reserves will be sufficient to fund the Company into the second half of 2028. Cantor’s own relationship with Eupraxia deserves disclosure. The report states that Cantor or its affiliates received investment-banking compensation from the company during the preceding 12 months, acted as lead or co-manager in an offering during that period, and makes a market in Eupraxia shares. Those relationships do not invalidate the analysis, but they belong beside the recommendation.

Why EPRX Merits Attention Ahead of the Catalyst

The strongest bullish reading of Cantor’s report is not that Eupraxia is guaranteed to become a blockbuster company. It is that the economics of a differentiated EoE treatment could become meaningful at relatively modest penetration, and that the December readout offers a near-term opportunity to test the clinical premise behind those economics. With a $19 formal price target, encouraging early durability observations and a U.S.-only valuation framework, Cantor presents a case for substantial upside if EP-104GI continues to deliver. The spreadsheet has made its argument. December’s clinical data must now make theirs.

The Sources

1. Cantor Fitzgerald — “Eupraxia EP-104GI (U.S. Only) EoE Valuation Simulations”
   October 7, 2026. Research report by Kristen Kluska, Ayan Hussein, Ph.D., and Ross Fladeland. Primary source for the $19 price target, Overweight rating, patient-population assumptions, sales scenarios, valuation methodology and analyst disclosures. Contact Cantor Fitzgerald to request to review complete report.
   
2. Eupraxia Pharmaceuticals “Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients”
   August 13, 2026. Company announcement supporting the discussion of swallowing symptoms, early durability observations and trial limitations. https://investors.eupraxiapharma.com/news-releases/news-release-details/eupraxia-pharmaceuticals-reports-symptom-response-data-its
   https://www.investing.com/news/company-news/eupraxia-reports-52week-data-from-eoe-treatment-trial-93CH-4925006
3. Sanofi — “FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis” May 20, 2022. Company announcement documenting Dupixent’s initial U.S. approval for EoE.
   https://www.sanofi.com/en/media-room/press-releases/2022/2022-05-20-19-15-00-2447906
4. U.S. Food and Drug Administration “Search Orphan Drug Designations and Approvals: Dupilumab”
   Regulatory record documenting Dupixent’s EoE approvals, including the expanded pediatric indication.
   https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=599317
5. Amgen “TEZSPIRE Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints” August 27, 2026. Company announcement supporting the discussion of Tezspire’s Phase 3 CROSSING results and competitive positioning. https://www.amgen.com/newsroom/press-releases/2026/08/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co-primary-and-all-key-secondary-endpoints
6. AstraZeneca “Tezspire Demonstrates Positive Phase III Results in Eosinophilic Esophagitis” August 27, 2026. Company announcement providing additional detail on the CROSSING trial’s efficacy findings. https://www.astrazeneca.com/media-centre/press-releases/2026/tezspire-crossing-trial-met-primary-endpoints.html
7. Pharmaphorum “FDA Changes Its Mind and Approves Takeda’s Eohilia”
   Coverage of Eohilia’s U.S. approval as an oral therapy for EoE. https://pharmaphorum.com/news/fda-changes-its-mind-and-approves-takedas-eohilia